Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $7.06 billion, representing a surprise of +7.27%. The company delivered an EPS surprise of +13.77%, with the consensus EPS estimate being $1.67.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Product Sales- Veklury- U.S. $108 million versus the three-analyst average estimate of $160.11 million. The reported number represents a year-over-year change of -70.3%.
Product Sales- Oncology- Trodelvy- U.S. $247 million versus $237.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.3% change.
Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S. $185 million versus $202.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.4% change.
Product Sales- HIV- Symtuza-Revenue share- U.S. $112 million versus the three-analyst average estimate of $109.94 million. The reported number represents a year-over-year change of +7.7%.
Total product sales- Total: $7.54 billion versus $7.06 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
Revenues- Royalty contract and other revenues: $33 million versus the eight-analyst average estimate of $49.91 million. The reported number represents a year-over-year change of -26.7%.
Product Sales- Oncology- Cell Therapy- Yescarta- Total: $390 million versus $386.44 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
Product Sales- HIV- Biktarvy- Total: $3.77 billion versus the seven-analyst average estimate of $3.46 billion. The reported number represents a year-over-year change of +21.4%.
Product Sales- HIV- Odefsey- Total: $336 million compared to the $314.11 million average estimate based on seven analysts. The reported number represents a change of -1.2% year over year.
Product Sales- HIV- Genvoya- Total: $470 million versus the seven-analyst average estimate of $482.51 million. The reported number represents a year-over-year change of -9.1%.
Product Sales- HIV- Descovy- Total: $616 million compared to the $573.59 million average estimate based on seven analysts. The reported number represents a change of +21% year over year.
Product Sales- Oncology- Trodelvy- Total: $355 million versus the seven-analyst average estimate of $281.97 million. The reported number represents a year-over-year change of +18.7%.
View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned +6.2% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing
Tuesday, June 10, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS), and The Boeing Co. (BA), as well as one micro-cap stock, Franklin Financial Services Corp. (FRAF). The Zacks microcap research is unique, as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page, and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Market Futures Have Fingers Crossed for Trade Deals Today's Featured Research Reports Shares of Johnson & Johnson have gained +5.8% over the past year against the Zacks Large Cap Pharmaceuticals industry's decline of -15.4%. The company's Innovative Medicine unit is showing a growth trend, driven by existing products like Darzalex, Tremfya, and Erleada, and continued uptake of new launches, including Spravato, Carvykti, and Tecvayli. J&J is making rapid progress with its pipeline and has been on an acquisition spree lately, which has strengthened its pipeline. However, sales in the MedTech segment have slowed down due to headwinds in Asia-Pacific markets like China and competitive pressure in some categories. The launch of Stelara generics is eroding the drug's sales in 2025. Uncertainty around talc lawsuits remains. (You can read the full research report on Johnson & Johnson here >>>) T-Mobile US' shares have outperformed the Zacks Wireless National industry over the past year (+33.4% vs. +28.3%). The company is gaining from healthy growth in service revenues driven by industry-leading postpaid net customer additions. In the first quarter, the company added 1.3 million postpaid net customers while postpaid net account additions were 205,000, both metrics being the best in the industry. Backed by robust demand for its postpaid services and cost discipline, the company has presented a bullish outlook for fiscal 2025. However, the highly competitive and saturated nature of the U.S. wireless market could adversely affect its financial results. (You can read the full research report on T-Mobile US here >>>) Shares of Boeing have outperformed the Zacks Aerospace - Defense industry over the past year (+17.2% vs. +15.5%). The company remains the largest U.S. aircraft manufacturer in the commercial aerospace sector. Soaring air travel should bolster the company's jet service business unit. The outlook for its defense business remains optimistic, buoyed by strengthening U.S. defense budget provisions. The acquisition of Spirit AeroSystems should strengthen Boeing's long-term revenue generation prospects. However, the shortage of labor continues to pose a threat to aerospace manufacturers like Boeing. Trade tensions between the United States and China may cause Boeing to be unsuccessful in the timely delivery of its 737 jets and thereby hurt its operational performance. (You can read the full research report on Boeing here >>>) Franklin Financial Services' shares have outperformed the Zacks Banks - Northeast industry over the past year (+35.7% vs. +17.0%). The company offers a compelling investment case supported by robust 11.2% loan growth driven by commercial real estate and residential lending, alongside a 15.7% rise in average loan balances. Strong deposit expansion of 18.1% enhances funding stability, with 85% of deposits insured or collateralized. The Wealth Management division boosts noninterest income and diversification, with AUM up 6.4%. A strategic $4.3 million securities restructuring enhances long-term profitability despite short-term earnings drag. (You can read the full research report on Franklin Financial Services here >>>) Other noteworthy reports we are featuring today include CrowdStrike Holdings, Inc. (CRWD), Schlumberger Ltd. (SLB), and Tesla, Inc. (TSLA). Mark VickerySenior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>> Today's Must Read J&J's (JNJ) Innovative Medicine Strong, MedTech Slows Down T-Mobile (TMUS) Rides on Healthy Demand, Strong Cash Flow Increasing Defense Orders Drive Boeing (BA), Amid Labor Shortage Featured Reports SLB Stock Positioned to Benefit From New Digital BusinessThe Zacks analyst projects SLB to gain from its New Digital segment by leveraging its extensive data resources and global expertise, positioning it as a leader in autonomy and AI-driven solutions. United Airlines (UAL) Rides on Air Travel Demand, Costs AilThe Zacks analyst is impressed with the fact that increased air-travel demand is aiding United Airlines' top-line performance. However, rising fuel costs continues to weigh on the bottom line. Improving Clearing and Transaction Fees Aid CME Group (CME)Per the Zacks analyst, CME is set to grow on higher clearing and transaction fees as market position, diverse derivative product lines and global reach drive volumes. However, escalating expense ails. New Order Volume Growth Aids Lennar (LEN), Macro Woes AilPer the Zacks analyst, Lennar is driving sales volume through is dynamic pricing model. However, ongoing affordability concerns in the housing market and high mortgage rates remain a concern. Post Holdings (POST) to Benefit From Solid Foodservice UnitPer the Zacks analyst, Post Holdings is likely to keep gaining from its Foodservice segment strength. Notably, unit sales grew 9.6% in the second quarter, backed by pricing and shake contributions. Powell (POWL) Gains From Strong Utility & Commercial MarketsPer the Zacks analyst, solid momentum across Powell's electric utility and commercial & other industrial markets, fueled by strong orders and healthy levels of project activity, will lend it momentum. CrowdStrike (CRWD) Rides on Product Strength, AcquisitionsPer the Zacks analyst, CrowdStrike is gaining from solid contributions of its growth-oriented products, primarily Falcon platform. Also, buyouts like Adaptive Shield and Flow Security are positive. New Upgrades Align Technology (ALGN) Banks on Solid Clear Aligner UptakePer the Zacks analyst, strong uptake of Align Technology's Invisalign DSP touch-up cases in North America supports Clear Aligner volume growth. Strength across APAC and EMEA regions is another plus. Focus on Alternatives to Support Affiliated Managers (AMG)Per the Zacks analyst, Affiliated Managers is well-placed for growth, driven by successful partnerships, global distribution capability, focus on alternative strategies, and a solid balance sheet. End-Market Strength & Diversification Aids Amphenol (APH)Per the Zacks analyst, Amphenol benefits from a diversified business model that lowers volatility of individual geographies. New Downgrades Backlog Decline and Tariff Woes to Weigh on Oshkosh (OSK)Falling backlog levels are likely to slow Oshkosh's revenue momentum, while tariff challenges could weigh on near-term margins, making the Zacks analyst bearish on the stock for now. Elevated Cost Inflation Hurt Conagra's (CAG) PerformancePer the Zacks analyst, Conagra is experiencing cost inflation for a while now, which is affecting its profitability. Higher input and protein costs are expected to persist into fiscal 2026. Tesla (TSLA) Hit by Falling Sales & Musk-Trump FeudTesla's EV sales are slipping across key markets including Europe and China. A public spat between CEO Musk and US President Trump has just made matters worse, per the Zacks analyst. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Schlumberger Limited (SLB) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report Franklin Financial Services Corp. (FRAF): Free Stock Analysis Report CrowdStrike (CRWD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Seeking China Exposure? Use This Zacks Screen
Zacks Thematic Screens lets you dive into 30 dynamic investment themes shaping the future. Whether you're interested in cutting-edge technology, renewable energy, or healthcare innovations, our themes help you invest in ideas that matter to you. For those interested in viewing the Thematic screens, please click here: >>> Thematic Screens – Zacks Investment Research. A top-ranked stock that the China Technology screen returned includes NetEase NTES. Let's take a closer dive into the screen before sizing up how NTES presently stands up. China Tech. China Tech. broadly refers to China-based technology companies across various domains. These firms are leaders in their respective fields and have created a niche market as Beijing aims to reduce reliance on Western technology amid escalating Sino-U.S. trade tensions. With Washington increasing restrictions on high-tech exports to the communist nation, Beijing has accelerated its efforts toward achieving self-sufficiency in critical industries. This has largely led to China's resurgence as a dominant force in the technology sector. The key technology aspects that have gained prominence in recent times are semiconductors, artificial intelligence, high-performance computing, industrial robots, data centers, satellites, quantum computing, and wireless broadband. This theme focuses on China-based technology companies listed on the U.S. stock market, including firms that provide Internet services, batteries, and online businesses such as e-commerce, online advertising, online media, online gaming, and social networking platforms. NetEase is an Internet technology company that develops applications, services, and other technologies for the Internet in China. Analysts have been notably bullish concerning its EPS outlook, raising expectations across the board in a big way over recent months. The stock sports the highly-coveted Zacks Rank #1 (Strong Buy). Image Source: Zacks Investment Research NetEase's quarterly results have been strong over recent periods, enjoying 7% revenue growth year-over-year throughout its latest period. The stock's success and favorable outlook have been driven by mega-popular games such as Marvel Rivals, which topped Steam's global top sellers chart shortly after its Season 2 update back in April. Below is a chart illustrating the company's sales on a quarterly basis. Image Source: Zacks Investment Research Bottom Line Zacks Thematic Screens lets you dive into 30 dynamic investment themes shaping the future. Whether you're interested in cutting-edge technology, renewable energy, or healthcare innovations, our themes help you invest in ideas that matter to you. Upon running the Zacks China Tech screen, top-ranked NetEase NTES was returned. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NetEase, Inc. (NTES) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
7 hours ago
- Yahoo
PepsiCo (PEP) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, PepsiCo (PEP) closed at $131.83, marking a +1.44% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.55% for the day. Meanwhile, the Dow gained 0.25%, and the Nasdaq, a tech-heavy index, added 0.63%. Shares of the food and beverage company witnessed a loss of 1.31% over the previous month, trailing the performance of the Consumer Staples sector with its gain of 1.91% and the S&P 500's gain of 6.29%. Investors will be eagerly watching for the performance of PepsiCo in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 17, 2025. The company is expected to report EPS of $2.04, down 10.53% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $22.37 billion, indicating a 0.6% downward movement from the same quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $7.87 per share and a revenue of $92.2 billion, representing changes of -3.55% and +0.38%, respectively, from the prior year. Any recent changes to analyst estimates for PepsiCo should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.18% lower. PepsiCo is currently a Zacks Rank #4 (Sell). With respect to valuation, PepsiCo is currently being traded at a Forward P/E ratio of 16.51. This expresses a discount compared to the average Forward P/E of 19.21 of its industry. We can also see that PEP currently has a PEG ratio of 3.73. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Beverages - Soft drinks was holding an average PEG ratio of 2.56 at yesterday's closing price. The Beverages - Soft drinks industry is part of the Consumer Staples sector. At present, this industry carries a Zacks Industry Rank of 45, placing it within the top 19% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PepsiCo, Inc. (PEP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
